WO1995015977A1 - Peptide representing antigenic epitopes of feline ige present on feline b-cells but not feline basophil cell surfaces - Google Patents
Peptide representing antigenic epitopes of feline ige present on feline b-cells but not feline basophil cell surfaces Download PDFInfo
- Publication number
- WO1995015977A1 WO1995015977A1 PCT/US1994/014407 US9414407W WO9515977A1 WO 1995015977 A1 WO1995015977 A1 WO 1995015977A1 US 9414407 W US9414407 W US 9414407W WO 9515977 A1 WO9515977 A1 WO 9515977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ige
- cells
- feline
- membrane
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 48
- 210000003651 basophil Anatomy 0.000 title abstract description 16
- 241000282324 Felis Species 0.000 title abstract description 10
- 230000000890 antigenic effect Effects 0.000 title abstract description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 abstract description 38
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 21
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 12
- 241000282326 Felis catus Species 0.000 abstract description 11
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 10
- 102000018358 immunoglobulin Human genes 0.000 abstract description 10
- 208000026935 allergic disease Diseases 0.000 abstract description 9
- 229940072221 immunoglobulins Drugs 0.000 abstract description 9
- 230000007815 allergy Effects 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 239000000523 sample Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 210000003630 histaminocyte Anatomy 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 6
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- PRNGXSILMXSWQQ-OEAJRASXSA-N Thr-Leu-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PRNGXSILMXSWQQ-OEAJRASXSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- AITKTFCQOBRJTG-CIUDSAMLSA-N Asp-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N AITKTFCQOBRJTG-CIUDSAMLSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- SUYRAPCRSCCPAK-VFAJRCTISA-N Leu-Trp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SUYRAPCRSCCPAK-VFAJRCTISA-N 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- -1 disulfosuccinimidyl tartarate Chemical compound 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002871 immunocytoma Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- IgE i munoglobulin E
- basophilic leukocytes basophils
- IgE molecules and hence, the underlying receptors for the Fc portion of IgE (FceR), and thereby triggers the release of pharmacologic mediators, such as histamine, the slow-reacting substance of anaphylaxis, and serotonin.
- pharmacologic mediators such as histamine, the slow-reacting substance of anaphylaxis, and serotonin.
- histamine the slow-reacting substance of anaphylaxis
- serotonin serotonin
- IgE is produced by a particular class of B lympphocytes (B cells), which also bear IgE on their surface. In individuals sensitized to specific allergens, the allergen-specific IgE is produced by B cells continuously.
- IgE binds to the receptors for the Fc of IgE (FceR) on the surface of basophils and mast cells very strongly.
- the association constant, Ka is in the neighborhood of 1 x 10 10 liter/mole and the "off" time is more than 20 hour.
- the very strong and stable association of IgE with FceR means that IgE is virtually always present on these cells.
- An immunotherapeutic agent targeting the IgE on B cells must not react with the IgE on basophils and mast cells.
- Antibodies which react with the IgE isotype will cross-link IgE and the underlying FceR on basophils and mast cells and, when administered in vivo, will induce systemic release of pharmacologic mediators, leading to anaphylaxis.
- IgE IgE.
- the plain antibodies can cause the pharmacological mechanism of antibody-dependent cellular cytotoxicity (ADCC), and the toxin- conjugated antibodies can directly cause cytolysis. Both of these mechanisms can lead to the depletion of IgE-bearing B cells without harming the basophils and mast cells.
- the IgE epitopes present on B cells but absent on basophils are termed ige.bl epitopes (bl stands for B lymphocytes).
- the invention relates to antigenic epitopes (and peptides).
- B cells express on their surface antibody molecules, which serve as receptors for antigens during immunological induction.
- the membrane- bound immunoglobulins differ from the secretory, soluble immunoglobulins synthesized by the same cells in that they have an extra peptidic piece that anchors them onto the B cell surface.
- These peptidic regions have lengths ranging from 41 to 72 amino acids, and can be divided into three segments in terms of locations in relation to the plasma membrane.
- the middle segments of 25 hydrophobic and uncharged amino acid residues are in the membrane lipid bilayer.
- the C terminal hydrophilic segments of 3-28 amino acid residues are intracellular.
- the segments toward N-terminus contain 13 to 27 amino acid residues and are highly acidic and hydrophilic. They are located on the extracellular surface of the plasma membrane. The length and the hydrophilic and highly charged nature of the extracellular segment indicates that this segment is exposed and accessible to antibodies.
- antigenic epitopes located on the extracellular segment of membrane-bound region of immunoglobulin heavy chains can be generally designated mb/ec, and the mb/ec segment of IgE is designated as the e. mb/ec segment.
- the present invention pertains to the discovery of feline e. mb/ec
- feline allergy treatment and for generating monoclonal and polyclonal antibodies which target the feline e. mb/ec epitopes on B cells.
- IgE is present on three cell types in the body: IgE-producing B cells, mast cells, and basophils. If an antigenic epitope of IgE is present on B cells and not on basophils and mast cells, these epitopes (defined as ige.bl) are virtually unique cell surface markers of IgE-bearing B cells.
- markers provide targets for several types of monoclonal or polyclonal antibody-based therapy for IgE-mediated allergic diseases, and provide a means to differentiate B cells producing IgE from B cells producing other isotypes.
- the peptidic anchor piece has three segments which are distinguishable based upon their locations in relation to the plasma membrane. Even though these peptidic pieces are short, ranging from 41 to 72 amino acid residues, and have often been referred to as the "membrane-bound domain", the peptides are not entirely in the membrane lipid bilayer. In fact, only 25 amino acid residues (which are the largely hydrophobic residues and threonine and serine) located in the middle part of the peptides, are in the lipid bilayer.
- the C-terminal, hydrophilic segments of 3 to 28 amino acid residues are located on the cytoplasmic side of the membrane.
- the segments toward the N-terminus, which are connected to the third or fourth constant domains of the immunoglobulin heavy chains (CH 3 or CH 4 ) are very hydrophilic and are on the extracellular side of the plasma membrane.
- the shortest of the extracellular segments of the membrane-bound pieces of me immunoglobulins (which are the mouse and rabbit ⁇ chains) have 13 amino acid residues.
- the mb/ec segments of all immunoglobulins contain high proportions of charged amino acid residues, and are almost entirely acidic residues.
- the proportions of charged amino acid residues and polar hydrophilic residues account for very high percentages of the amino acid composition of the mb/ec segment.
- the murine or rat e. mb/ec segment has 19 amino acid residues, among them 8 Glu and 2 Asp residues.
- the starting point is the mRNA preparation of a human myeloma cell line which expresses IgE on the surface, for example, SK007 cells.
- the mRNA preparation one can establish a cDNA library employing cloning vectors with ⁇ phage or plasmids.
- a preferred method for constructing me cDNA library is with the cDNA Library Construction System Kit - Librarian I; developed and commercialized by Invitrogen (San Diego, CA).
- a stepwise detailed instruction manual is provided for RNA isolation from cells, reverse transcription, second strand synthesis, linker ligation, agarose gel sizing of cDNA, electroelution to purify cDNA vector ligation, and transformation of E. coli.
- the vector used in this library is pDCM8.
- the library can be screened with a DNA probe a, which is a 1.1 kb long U266 cDNA covering most of length of e mRNA (no membrane-bound secreted and membrane-bound forms can be distinguished by using additional probes).
- a probe b is developed by taking advantage of the likelihood that the end of the CH 4 domain is truncated in the human e chain of the membrane- bound form. The truncation occurs where gene segments of CH 4 domain and the membrane-bound domain are translocated.
- Probe b will react with secreted form of e chain gene and not the membrane-bound form of the e chain gene.
- the design of a probe c is based on the finding that the transmembrane segment of the membrane-bound domain (mb/tm segment) is very conserved among all the immunoglobulin genes so far sequenced.
- a probe d which represents a segment upstream to the most possible splicing donor site, GT, consists of 36 bp. This probe should react with the e chain gene of both the secreted and membrane-bound forms.
- the location of probes a, b, c, and d, in schematic form, is shown in U.S. Patent No. 5,091,313.
- Table 1 summarizes the pattern of reactivities of clones containing e genes of secreted or membrane-bound immunoglobulins with the four probes.
- the library size needed to clone the membrane-bound e chain depends on how abundant the mRNA is. Assuming secreted IgE comprises 0.1 % of the SK007 poly A + RNA, the library size should be about 5,000 independent recombinant clones, in order to have a 99% possibility of isolating a positive clone. In IgE-producing rat immunocytoma IR2 and IR162 cells, mRNA for the membrane-bound form of e chain was found to be more than 2% of that of the secreted form.
- the cDNA library size needed to isolate the membrane-bound e chain is about 250,000. In a preferred procedure, a larger number of clones, about 1 ,000,000, are screened.
- PCR polymerase chain reaction
- the strategy is to amplify both the secreted and membrane-bound forms of the e chains.
- Two primers are to be used, one is oligo.dT (25-30-mers) and one is the oligomer corresponding to probe d.
- Probe d is located 5' to the most possible splicing donor site and therefore primes both the secreted and membrane-bound forms of e mRNA and DNA. After sufficient amplification, the two populations of DNA fragments are resolved by gel electrophoresis. The secreted form of the e chain can be distinguished by its reactivity with probe b. The purified DNA is then subjected to DNA sequencing. PCR amplification seems to be a more efficient procedure than cDNA cloning for mRNA poorly represented in the poly A + RNA pool.
- the U266 e chain cDNA can be used to work out some preliminary
- Another approach for obtaining a DNA clone containing genes encoding the membrane-bound segments is to screen the human genomic DNA library.
- the human genomic DNA library is readily available.
- a preferred source is the library constructed using human lung fibroblasts
- WI38 cells provided by Stratagene (La Jolla, CA).
- the genes are in ⁇ vector and the inserted DNA have average sizes of 15K bp.
- Identification of the clones can be achieved by hybridization with U266 cDNA.
- the location of the gene segment corresponding to the membrane-bound region can be determined by using a probe prepared from the homologous mouse gene of the transmembrane segment (probe c, discussed above).
- the sequence of the membrane-bound segment is then determined, and this sequence is shown in U.S. Patent No. 5,091,313.
- Nucleotide sequence of genomic DNA encompassing the encoding segments for the membrane anchoring peptide of human membrane bound e chain was determined as described above.
- the assignment of the exons was made by identifying the nucleotides for splicing donors and acceptors, and by comparing them to the published homologous sequences of mouse membrane-bound e chain, as well as to immunoglobulins of other classes.
- the peptides can be chemically synthesized by standard techniques of protein synthesis.
- a preferred method for synthesizing the peptides is with the RaMPS system (DuPont, Wilmington, DE), which applies Fmoc chemistry.
- the proteins can be biosynthesized by employing oligodeoxynucleotides encoding the peptides.
- the peptides may be used in either the monomeric or dimeric structural forms shown in Patent No. 5,091,313. Peptides comprising the human e. mb/ec segment and the connecting four amino acids in the CH 4 domain can also be used.
- modified peptides having substantial immunological equivalency can be used.
- the peptide amino acid sequence shown above (or described below for dogs) can be modified by deletion, insertion or substimtion of one or more amino acids which do not essentially detract from the immunological properties of the peptide.
- the peptides can also be used as polymers where the amino acid sequence shown above, or equivalent
- sequence is the polymer repeat unit.
- Bluescript cloning vector and me plasmid DNA was used for nucleotide sequencing. Two exons wim homology to dog IgE membrane exons ml and m2, respectively, were identified within this plasmid subclone.
- the DNA sequence of the cat ml exon, together with its translated amino acid sequence, is shown in SEQ ID NO: l .
- the cat migis-e sequence is tentatively defined as the first 19 amino acid residues of the ml region based on the hydrophilicity analysis. Comparison of the migis-e peptide sequence between dog and cat showed that, in addition to an amino acid change at position 15 (Tyr in the cat and Glu in the dog), there is a homologous amino acid replacement at position
- the e. mb/ec peptide can be used in the immunization of animals to prepare polyclonal and monoclonal antibodies. They can also be used to screen for specific monoclonal antibodies or characterize specific polyclonal antibodies. They can also be used to purify monoclonal and polyclonal antibodies.
- the immunogen may be the membrane-bound IgE isolated from plasma
- immunogen may also be the IgE-bearing myeloma cells themselves.
- the immunogen can also be the purified dog IgE described above.
- synthetic e. mb/ec peptide it is more effective to conjugate the peptide to a protein carrier.
- a preferred protein carrier is keyhole limpet hemocyanin (KLH). If the peptidic
- the modified synthetic peptidic will have two amino groups for linking. Multiple molecules of peptides can be conjugated to each molecule
- Cross-linkers such as glutaraldehyde or bis (sulfosuccinimidyl) suberate or disulfosuccinimidyl tartarate (Catalogue #21579, 20591 , Pierce
- the immunogen such as the KLH conjugate
- the immunogen can be used to immunize rabbits, goats, rats, or mice to prepare polyclonal antibodies specific for the e. mb/ec peptide.
- Lympocytes from the spleen or lymph nodes of immune mice and rats can also be taken to prepare hybridomas secreting monoclonal antibodies specific for the e. mb/ec peptide.
- a preferred protocol to prepare the monoclonal antibodies is to fuse immune spleen cells of mice with non-secreting mouse myeloma cells, such as NS- 1 or SP2/0 cells using polyethylene glycol.
- mice 50 ⁇ g of the peptide-KLH conjugate in complete Fruend's adjuvant is injected subcutaneously into each mouse for priming. Two and four weeks later, the same amounts of antigen are given s.c. in incomplete Freund's adjuvant. At about the six week time point, the fourth antigen injection is given i.p. in saline. Mice are sacrificed 4 days after the last injection and the spleens are taken for
- SK007 cells When human IgE-bearing cells are used as the immunogen, lxlO 7 cells are injected i.p. at two week intervals.
- the screening of hybridomas for monoclonal antibodies, or the identification of polyclonal antibodies or the identification of polyclonal antibodies reactive with e. mb/ec peptide can be performed with enzyme linked immunosorbent assays (ELISAs), using the synthetic e. mb/ec peptide as the solid phase antigen.
- ELISAs enzyme linked immunosorbent assays
- An alternative solid phase antigen is the conjugate of e. mb/ec peptide with a different carrier protein such as bovine serum albumin different from that used in the immunogen.
- monoclonal and polyclonal antibodies bind to an e. mb/ec peptide, or to IgE- bearing B cells, but do not bind to soluble IgE, or to IgE on basophils or mast cells (as measured by a histamine release assay).
- the peptides of the invention can be used to treat animals which are afflicted with allergies or other immediate-type hypersensitivities; for example, the cat e. mb/ec peptide can be used to treat cat allergies or hypersensitivities. Similarly, me corresponding e. mb/ec peptides from horses or other mammals, could be used to treat these animals.
- the e. mb/ec peptides When used to treat animals, the e. mb/ec peptides, with a suitable carrier such as a recombinant protein antigen from rabies virus or from feline leukemia virus, are administered to the animal in a suitable pharmaceutical vehicle.
- a suitable carrier such as a recombinant protein antigen from rabies virus or from feline leukemia virus
- Sub-cutaneous or intra-muscular injection is preferred as a route of administration.
- the dosage of peptide administered can vary widely depending on the size of the animal, but should be sufficient to create an immunogenic response in the animal. This would generally be in the range of about 10-100 ⁇ g/kg of animal body weight. 8. Animal Model Experiments.
- mice are not known to develop allergic symptoms naturally.
- the mouse can serve as a model.
- the e. mb/ec segment of the mouse has already been sequenced.
- the e. mb/ec peptide is synthesized in several forms, including one that has extra Leu-Lys residues at the C-terminus.
- KLH conjugate could be used as the essential vaccine component, to immunize mice. One then examines whether the vaccine induces
- Antibodies against e. mb/ec epitopes can be used to identify and enumerate IgE-bearing lymphocytes in a fluid sample, such as serum.
- a fluid sample such as serum.
- species e.g. , cats
- antibodies can be used in standard assay formats for determining cell surface antigens.
- the antibody is contacted with a sample of the leukocytes to be tested under conditions which allow the antibody to bind IgE-bearing cells in the sample.
- the cells are then examined for binding of antibody. This can be accomplished by conventional cell staining procedures.
- a fluorescently labeled second antibody can be used to detect binding of the anti-IgE antibody.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the feline B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. The epitope can be exploited for therapy and diagnosis. For example, peptides representing the epitopes associated with the anchor domain of IgE can be used to generate antibodies against these regions, for use in cat allergy therapy and analysis of cat IgE-bearing B lymphocytes.
Description
PEPTIDE REPRESENTING ANTIGENIC EPITOPES OF FELINE IGE PRESENT ON FELI B-CELLS BUT NOT FELINE BASOPHIL CELL SURFACES
Background
The immediate-type hypersensitivities, such as extrinsic asthma, hay fever, and allergic responses to certain food or drugs, are mediated primarily by i munoglobulin E (IgE). In an IgE-mediated allergic response, the allergen binds to IgE on the surface of mast cells and
basophilic leukocytes (basophils). This binding causes a crosslinking of
the IgE molecules and hence, the underlying receptors for the Fc portion of IgE (FceR), and thereby triggers the release of pharmacologic mediators, such as histamine, the slow-reacting substance of anaphylaxis, and serotonin. The release of these mast cell and basophil products causes the various pathological manifestations of allergy.
IgE is produced by a particular class of B lympphocytes (B cells), which also bear IgE on their surface. In individuals sensitized to specific allergens, the allergen-specific IgE is produced by B cells continuously.
IgE binds to the receptors for the Fc of IgE (FceR) on the surface of basophils and mast cells very strongly. The association constant, Ka, is in the neighborhood of 1 x 1010 liter/mole and the "off" time is more than 20 hour. The very strong and stable association of IgE with FceR means that IgE is virtually always present on these cells. An immunotherapeutic agent targeting the IgE on B cells must not react with
the IgE on basophils and mast cells. Antibodies which react with the IgE isotype will cross-link IgE and the underlying FceR on basophils and mast cells and, when administered in vivo, will induce systemic release of pharmacologic mediators, leading to anaphylaxis.
The development of monoclonal antibodies that recognize an
antigenic epitope present on the IgE on B cells, but not the IgE on basophils, was described in International Application Serial No.
PCT/US88/04706. These antibodies also bind to the secreted form of
IgE. In addition, the me od of using such antibodies for treating allergy, either in the form of plain antibodies or toxin-conjugated antibodies, was described. The plain antibodies can cause the pharmacological mechanism of antibody-dependent cellular cytotoxicity (ADCC), and the toxin- conjugated antibodies can directly cause cytolysis. Both of these mechanisms can lead to the depletion of IgE-bearing B cells without harming the basophils and mast cells. The IgE epitopes present on B cells but absent on basophils are termed ige.bl epitopes (bl stands for B lymphocytes).
If a vaccine was developed which induced production of antibodies which could specifically target IgE-bearing B cells, without targeting any other cells, such a vaccine would be useful in treating allergy and related hypersensitivities. It has been observed that IgE is not needed for normal
health, except perhaps for combatting parasites. Thus, depleting all IgE- bearing B cells would not produce any adverse effects.
Summary of the Invention
The invention relates to antigenic epitopes (and peptides
representing these epitopes) which are present on feline B cell membrane- bound immunoglobulins but not on the secreted, soluble form of the immunoglobulin. The invention also pertains to methods of exploiting these newly discovered epitopes for therapeutic and diagnostic purposes. B cells express on their surface antibody molecules, which serve as receptors for antigens during immunological induction. The membrane- bound immunoglobulins differ from the secretory, soluble immunoglobulins synthesized by the same cells in that they have an extra peptidic piece that anchors them onto the B cell surface.
All ten membrane-bound immunoglobulins on B cells from different species, for which amino acid sequences have been determined, have extra isotype-specific regions that anchor the immunoglobulins to the membrane. These peptidic regions have lengths ranging from 41 to 72 amino acids, and can be divided into three segments in terms of locations in relation to the plasma membrane. The middle segments of 25 hydrophobic and uncharged amino acid residues are in the membrane lipid bilayer. The C terminal hydrophilic segments of 3-28 amino acid residues are intracellular. The segments toward N-terminus contain 13 to 27 amino acid residues and are highly acidic and hydrophilic. They are located on the extracellular surface of the plasma membrane.
The length and the hydrophilic and highly charged nature of the extracellular segment indicates that this segment is exposed and accessible to antibodies. These antigenic epitopes located on the extracellular segment of membrane-bound region of immunoglobulin heavy chains can be generally designated mb/ec, and the mb/ec segment of IgE is designated as the e. mb/ec segment.
The present invention pertains to the discovery of feline e. mb/ec
epitopes and peptides representing them, and the use of such peptides for
feline allergy treatment and for generating monoclonal and polyclonal antibodies which target the feline e. mb/ec epitopes on B cells.
Detailed Description of the Invention
1. Unique Antigenic Epitopes of IgE as Targets of Immunotherapeutic Agents
IgE is present on three cell types in the body: IgE-producing B cells, mast cells, and basophils. If an antigenic epitope of IgE is present on B cells and not on basophils and mast cells, these epitopes (defined as ige.bl) are virtually unique cell surface markers of IgE-bearing B cells.
These markers provide targets for several types of monoclonal or polyclonal antibody-based therapy for IgE-mediated allergic diseases, and provide a means to differentiate B cells producing IgE from B cells producing other isotypes.
2. Anchoring Peptidic Piece of B Cell Membrane-Bound Immunoglobulins
The amino acid sequence data of the ten membrane-bound
immunoglobulins from several species have been determined. See Ishida,
N. et al. , EMBO J. , 1: 1117 (1982); Steen, M. L. et al. , J. Mol. Biol. ,
177: 19-32 (1984); Rogers, J. et al. , Cell, 26: 19-27 (1981); Yamawaki- Kataoka, Y. et al. , Proc. Natl. Acad. Sci. , USA, 79:2008-2012 (1982);
Kamaromy, M. et al. , Nuc. Acids Res. , 11:6775-6785 (1983); Rogers, J. et al. , Cell, 20:303-312 (1980); Bernstein, K. E. , J. Immunol. 132:490-
495 (1984); Cheng, H. et al. , Nature, 296:410-415 (1982). These sequences indicate certain common features of the plasma membrane- bound peptidic piece. The peptidic anchor piece has three segments which are distinguishable based upon their locations in relation to the plasma membrane. Even though these peptidic pieces are short, ranging from 41 to 72 amino acid residues, and have often been referred to as the "membrane-bound domain", the peptides are not entirely in the membrane lipid bilayer. In fact, only 25 amino acid residues (which are the largely hydrophobic residues and threonine and serine) located in the middle part of the peptides, are in the lipid bilayer. The C-terminal, hydrophilic segments of 3 to 28 amino acid residues are located on the cytoplasmic side of the membrane. The segments toward the N-terminus, which are connected to the third or fourth constant domains of the immunoglobulin heavy chains (CH3 or CH4) are very hydrophilic and are on the extracellular side of the plasma membrane.
The shortest of the extracellular segments of the membrane-bound pieces of me immunoglobulins (which are the mouse and rabbit μ chains) have 13 amino acid residues. The mb/ec segments of all immunoglobulins contain high proportions of charged amino acid residues, and are almost entirely acidic residues. The proportions of charged amino acid residues and polar hydrophilic residues account for very high percentages of the amino acid composition of the mb/ec segment. These parameters indicate
that all the mb/ec segments are exposed and long enough to be accessible by antibodies. Studies of the evolution of immunoglobulin heavy chains indicate the e and y chains are more related to each other (had more recent common ancestry) than to other chains (Lin, L. C. and Putnam, F. W., Proc. Natl. Acad. Sci. USA, 1981). In addition, the heavy chains evolved before the various mammals species, such as mice, rats, and humans, evolved. The murine or rat e. mb/ec segment has 19 amino acid residues, among them 8 Glu and 2 Asp residues.
3. Determining the Amino Acid Sequence of the Human e. mb/ec Segment.
A number of well established procedures can be applied to determine the DNA sequence corresponding to the human e. mb/ec segment. In one approach, the starting point is the mRNA preparation of a human myeloma cell line which expresses IgE on the surface, for example, SK007 cells. With the mRNA preparation, one can establish a cDNA library employing cloning vectors with λ phage or plasmids. A
preferred method for constructing me cDNA library is with the cDNA Library Construction System Kit - Librarian I; developed and commercialized by Invitrogen (San Diego, CA). A stepwise detailed instruction manual is provided for RNA isolation from cells, reverse transcription, second strand synthesis, linker ligation, agarose gel sizing of cDNA, electroelution to purify cDNA vector ligation, and transformation of E. coli. The vector used in this library is pDCM8.
In the screening of the cDNA library for clones containing the e. mb/ec segment, several probes can be used. The library can be screened with a DNA probe a, which is a 1.1 kb long U266 cDNA covering most of length of e mRNA (no membrane-bound secreted and membrane-bound forms can be distinguished by using additional probes). A probe b is developed by taking advantage of the likelihood that the end of the CH4 domain is truncated in the human e chain of the membrane- bound form. The truncation occurs where gene segments of CH4 domain and the membrane-bound domain are translocated. The loss of C-termini occur with the membrane-bound forms of immunoglobulins, including e and λ, which contain CH4 domains. From the published information on the nucleotide sequence of the human e CH4 domain, the most probable splicing donor site is intracodon GT, 71 bp 5' of the termination codon
TGA. Another GT, which is not intracodon and less likely a splicing donor site, is closer to the terminus (24 bp 5' to the termination codon).
Probe b will react with secreted form of e chain gene and not the membrane-bound form of the e chain gene.
The design of a probe c is based on the finding that the transmembrane segment of the membrane-bound domain (mb/tm segment) is very conserved among all the immunoglobulin genes so far sequenced.
There is a segment of peptide and its corresponding coding DNA within
this mb/tm segment that is nearly identical among all immunoglobulins.
A probe d, which represents a segment upstream to the most possible splicing donor site, GT, consists of 36 bp. This probe should react with the e chain gene of both the secreted and membrane-bound forms. The location of probes a, b, c, and d, in schematic form, is shown in U.S. Patent No. 5,091,313.
Table 1 summarizes the pattern of reactivities of clones containing e genes of secreted or membrane-bound immunoglobulins with the four probes.
Table 1. The reactivity of e gene-containing cDNA clones with probes a, b, c, and d.
e Secreted e Membrane-bound
Probe a + +
Probe b + -
Probe c - +
Probe d + +
The library size needed to clone the membrane-bound e chain depends on how abundant the mRNA is. Assuming secreted IgE comprises 0.1 % of the SK007 poly A+ RNA, the library size should be about 5,000 independent recombinant clones, in order to have a 99% possibility of isolating a positive clone. In IgE-producing rat immunocytoma IR2 and IR162 cells, mRNA for the membrane-bound form of e chain was found to be more than 2% of that of the secreted form. Assuming this ratio of membrane-bound/secreted forms of e chain holds true for the human IgE-producing SK007 cells, the cDNA library size needed to isolate the membrane-bound e chain is about 250,000. In a preferred procedure, a larger number of clones, about 1 ,000,000, are screened.
An alternative to the conventional approach of establishing a cDNA library and screening the clones representing the cellular mRNA species, is to amplify the mRNA to produce high proportions of their corresponding DNA. The resulting DNA can then be purified by gel
electrophoresis and subjected to sequence analysis. The methodology, referred to as polymerase chain reaction (PCR) amplification, has been established in the past few years and a complete system, including reagents and equipment, have been commercialized. One preferred system is provided by Perkin Elmer Cetus (Norwalk, CT). The reagent kit is the GeneAmp DNA Amplification Reagent Kit and the equipment is the DNA Thermal Cycler.
Some of the specific reagents used in this approach are the same
as used for the cDNA library cloning. Since no sequence in the membrane-bound segment of the e chain has been determined, the strategy is to amplify both the secreted and membrane-bound forms of the e chains. Two primers are to be used, one is oligo.dT (25-30-mers) and one is the oligomer corresponding to probe d. Probe d is located 5' to the most possible splicing donor site and therefore primes both the secreted and membrane-bound forms of e mRNA and DNA. After sufficient amplification, the two populations of DNA fragments are resolved by gel electrophoresis. The secreted form of the e chain can be distinguished by its reactivity with probe b. The purified DNA is then subjected to DNA sequencing. PCR amplification seems to be a more efficient procedure than cDNA cloning for mRNA poorly represented in the poly A+ RNA pool.
The U266 e chain cDNA can be used to work out some preliminary
annealing conditions between template DNA and the oligo-primers.
Another approach for obtaining a DNA clone containing genes encoding the membrane-bound segments is to screen the human genomic DNA library. The human genomic DNA library is readily available. A preferred source is the library constructed using human lung fibroblast
WI38 cells provided by Stratagene (La Jolla, CA). The genes are in λ vector and the inserted DNA have average sizes of 15K bp. Identification of the clones can be achieved by hybridization with U266 cDNA. The location of the gene segment corresponding to the membrane-bound region can be determined by using a probe prepared from the homologous mouse gene of the transmembrane segment (probe c, discussed above). The sequence of the membrane-bound segment is then determined, and this sequence is shown in U.S. Patent No. 5,091,313. Nucleotide sequence of genomic DNA encompassing the encoding segments for the membrane anchoring peptide of human membrane bound e chain was determined as described above. The assignment of the exons was made by identifying the nucleotides for splicing donors and acceptors, and by comparing them to the published homologous sequences of mouse membrane-bound e chain, as well as to immunoglobulins of other classes.
Two exons were found to exist.
Human e. mb/ec peptide is identified as the first fourteen amino acids encoded by membrane exon I. This precedes a stretch of about 25 hydrophobic amino acids which are the transmembrane region. Two possible structures of e. mb/ec are shown in U.S. Patent No. 5,091 ,313. As described more fully below, the e. mb/ec peptides (from both humans and other species) can be used to elicit antibodies which react specifically with membrane-bound immunoglobulin e. For this purpose,
the peptides can be chemically synthesized by standard techniques of protein synthesis. A preferred method for synthesizing the peptides is with the RaMPS system (DuPont, Wilmington, DE), which applies Fmoc chemistry. Alternatively, the proteins can be biosynthesized by employing oligodeoxynucleotides encoding the peptides.
As immunogens or vaccines, the peptides may be used in either the monomeric or dimeric structural forms shown in Patent No. 5,091,313. Peptides comprising the human e. mb/ec segment and the connecting four amino acids in the CH4 domain can also be used. In addition, modified peptides having substantial immunological equivalency can be used. For example, the peptide amino acid sequence shown above (or described below for dogs) can be modified by deletion, insertion or substimtion of one or more amino acids which do not essentially detract from the immunological properties of the peptide. The peptides can also be used
as polymers where the amino acid sequence shown above, or equivalent
sequence, is the polymer repeat unit.
4. Sequencing the Cat e. mb/ec Segment.
A total of 5 x 105 recombinant bacteriophage plaques from a feline genomic library (purchased from Stratagene, Inc.) were screened by using a 32P-labeled dog Ce cDNA probe. One phage clone was shown to contain sequences homologous to both the constant region and membrane domain of the dog IgE. (See U.S. Application Serial No. 08/031 ,398
(incorporated by reference) for tfiese dog sequences.). A 1.6kb Ncol/Hpal DNA fragment containing the membrane domain was subcloned into a
Bluescript cloning vector and me plasmid DNA was used for nucleotide sequencing. Two exons wim homology to dog IgE membrane exons ml and m2, respectively, were identified within this plasmid subclone. The DNA sequence of the cat ml exon, together with its translated amino acid sequence, is shown in SEQ ID NO: l .
The cat migis-e sequence is tentatively defined as the first 19 amino acid residues of the ml region based on the hydrophilicity analysis. Comparison of the migis-e peptide sequence between dog and cat showed that, in addition to an amino acid change at position 15 (Tyr in the cat and Glu in the dog), there is a homologous amino acid replacement at position
6 (Asp in the cat and Glu in the dog), and at position 12 (Ala in the cat and Thr in the dog).
6. Developing Antibodies to the e. mb/ec Segment.
The e. mb/ec peptide can be used in the immunization of animals to prepare polyclonal and monoclonal antibodies. They can also be used to screen for specific monoclonal antibodies or characterize specific polyclonal antibodies. They can also be used to purify monoclonal and polyclonal antibodies.
In the process of preparing for monoclonal antibodies specific for
e. mb/ec peptide, it is not necessary to use the e. mb/ec peptide in both immunization and antibody identification. For example, in immunizing mice for preparing immune spleen cells for fusion with myeloma cells, the immunogen may be the membrane-bound IgE isolated from plasma
membrane of IgE-bearing myeloma cells, such as SK007 cells. The
immunogen may also be the IgE-bearing myeloma cells themselves. The immunogen can also be the purified dog IgE described above. For using the synthetic e. mb/ec peptide as the immunogen, it is more effective to conjugate the peptide to a protein carrier. A preferred protein carrier is keyhole limpet hemocyanin (KLH). If the peptidic
segment lacks a lysine residue or if the lysine residue is in the middle part
of the segment, it is desirable to add a lysine residue at the C-terminal end. Because the N-terminus already has an α-amino group, the modified synthetic peptidic will have two amino groups for linking.
Multiple molecules of peptides can be conjugated to each molecule
of the carrier protein. With KLH, a preferred molar ratio for peptide/KLH is 10. The method of conjugation is very well established.
Cross-linkers such as glutaraldehyde or bis (sulfosuccinimidyl) suberate or disulfosuccinimidyl tartarate (Catalogue #21579, 20591 , Pierce
Chemical Co. , Rockford, IL) have been used. A preferred cross-linker is the latter.
The immunogen, such as the KLH conjugate, can be used to immunize rabbits, goats, rats, or mice to prepare polyclonal antibodies specific for the e. mb/ec peptide. Lympocytes from the spleen or lymph nodes of immune mice and rats can also be taken to prepare hybridomas secreting monoclonal antibodies specific for the e. mb/ec peptide. A preferred protocol to prepare the monoclonal antibodies is to fuse immune spleen cells of mice with non-secreting mouse myeloma cells, such as NS- 1 or SP2/0 cells using polyethylene glycol.
In one immunization protocol for mice, 50 μg of the peptide-KLH conjugate in complete Fruend's adjuvant is injected subcutaneously into each mouse for priming. Two and four weeks later, the same amounts of antigen are given s.c. in incomplete Freund's adjuvant. At about the six week time point, the fourth antigen injection is given i.p. in saline. Mice are sacrificed 4 days after the last injection and the spleens are taken for
preparing single cell suspension for fusion with myeloma cells. A similar
protocol can also be used for immunization with purified native human membrane-bound IgE (having attached membrane anchor domain) isolated from the plasma membrane of IgE-bearing human myeloma cells, such as
SK007 cells. When human IgE-bearing cells are used as the immunogen, lxlO7 cells are injected i.p. at two week intervals.
The fusion procedure with polyethylene glycol and other various procedures concerning cloning and hybridoma culturing have been well
established, and the preferred protocol is the same as described by
Hudson, L. and Hay. F.C. , (Practical Immunology. 2nd edition, pp. 303- 313, Blackwell Publishing Co. , Boston). The screening of hybridomas for monoclonal antibodies, or the identification of polyclonal antibodies or the identification of polyclonal antibodies reactive with e. mb/ec peptide can be performed with enzyme linked immunosorbent assays (ELISAs), using the synthetic e. mb/ec peptide as the solid phase antigen. An alternative solid phase antigen is the conjugate of e. mb/ec peptide with a different carrier protein such as bovine serum albumin different from that used in the immunogen. Further characteristics of the monoclonal and polyclonal antibodies would be that they bind to an e. mb/ec peptide, or to IgE- bearing B cells, but do not bind to soluble IgE, or to IgE on basophils or mast cells (as measured by a histamine release assay).
7. Using the e. mb/ec Peptides for Animal Treatment
The peptides of the invention can be tested in animal model
systems to determine if they are suitable for allergy treatment in humans.
Also, the peptides of the invention can be used to treat animals which are afflicted with allergies or other immediate-type hypersensitivities; for example, the cat e. mb/ec peptide can be used to treat cat allergies or hypersensitivities. Similarly, me corresponding e. mb/ec peptides from horses or other mammals, could be used to treat these animals.
When used to treat animals, the e. mb/ec peptides, with a suitable carrier such as a recombinant protein antigen from rabies virus or from feline leukemia virus, are administered to the animal in a suitable pharmaceutical vehicle. Sub-cutaneous or intra-muscular injection is preferred as a route of administration. The dosage of peptide administered can vary widely depending on the size of the animal, but should be sufficient to create an immunogenic response in the animal. This would generally be in the range of about 10-100 μg/kg of animal body weight. 8. Animal Model Experiments.
One could also test the use of e. mb/ec peptides in vaccination in a mouse model system, as described below. Mice are not known to develop allergic symptoms naturally. However, for demonstrating the pharmacologic mechanisms of the intended therapy in regard to the depletion of IgE-bearing B cells and IgE, the mouse can serve as a model.
The e. mb/ec segment of the mouse has already been sequenced.
Ishida, N. et al., EMBO J. 1: 1117-1123 (1982). The 19 amino acid residue peptide is shown in that publication.
The e. mb/ec peptide is synthesized in several forms, including one that has extra Leu-Lys residues at the C-terminus. The peptide or its
KLH conjugate could be used as the essential vaccine component, to immunize mice. One then examines whether the vaccine induces
antibodies which target the IgE-bearing B cells, by examining the
following questions: (a) Does the total IgE in circulation decline?
(b) Does the number of IgE-bearing B cells decline?
(c) Does the density of IgE on the surface of basophils decline?
(d) Do IgM and IgG specific for e. mb/ec peptide cause different effects? The purpose of this question is to address the effects of antibody dependent cellular cytotoxicity (ADCC) in the depletion of IgE-bearing B cells. IgG, not IgM, is known to mediate ADCC.
9. Diagnostic Uses for the Antibodies of the Invention.
Antibodies against e. mb/ec epitopes can be used to identify and enumerate IgE-bearing lymphocytes in a fluid sample, such as serum.
Thus, the various antibodies which target the e. mb/ec epitope of a
particular species (e.g. , cats) can be used diagnostically in that species for such identification and enumeration of its IgE-bearing B lymphocytes.
For this purpose, antibodies can be used in standard assay formats for determining cell surface antigens. In general, the antibody is contacted with a sample of the leukocytes to be tested under conditions which allow the antibody to bind IgE-bearing cells in the sample. The cells are then examined for binding of antibody. This can be accomplished by conventional cell staining procedures. For example, a fluorescently labeled second antibody can be used to detect binding of the anti-IgE antibody. Equivalents
The terms, expressions and examples herein are exemplary only and not limiting, and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
SEQUENCE LISTING
1) General Information: i) Applicant: Chang, Tse Wen ii) Title of Invention: PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF FELINE IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE iii) Number of Sequences: 1 iv) Correspondence Address:
A) Addressee: Tanox Biosystems, Inc.
B) Street: 10301 Stella Link Rd.
C) City: Houston
D) State: Texas
E) Country: USA
F) Zip: 77025 v) Computer Readable Form:
A) Medium Type: Diskette, 3.5 inch
B) Computer: IBM PS/2
C) Operating System: DOS 3.30
D) Software: Wordperfect 5.1 vi) Current application data:
A) Application Number:
B) Filing Date:
C) Classification: vii) Prior Application Data:
A) Application Number: 08/164,910
B) Filing Date: 12/09/1993 viii) Attorney/ Agent Information:
A) Name: Mirabel, Eric P.
B) Registration Number: 31,211
C) Reference/Docket Number: TNX88-03EEE-PCT ix) Telecommunication Information:
A) Telephone: (713) 664-2288
B) Telefax: (713) 664-8914
2) Information for SEQ ID NO: l : i) Sequence Characteristics:
A) Length: 135 nucleotides
B) Type: nucleic acid
C) Strandedness: double stranded
D) Topology: linear xi) Sequence Description: SEQ ID NO: l
GAG CTG GAG CTC CAG GAC CTG TGT GCG GAC GCC GCT GAG 39 Glu Leu Glu Leu Gin Asp Leu Cys Ala Asp Ala Ala Glu
5 10
AGC TAC GAG CTG GAC GAG CTG TGG ACC AGC CTG CTG GTC 78
Ser Tyr Glu Leu Asp Glu Leu Trp Thr Ser Leu Leu Val 15 20 25
TTC ATC ACC CTC TTC CTG CTC AGC GTG AGC TAC GGA GCC 117
Phe lie Thr Leu Phe Leu Leu Ser Val Ser Tyr Gly Ala 30 35
GCC ATC ACC CTC TTC AAG 135 Ala lie Thr Leu Phe Lys 40 45
Claims
1. A peptide corresponding to the e. mb/ec segment of a cat.
2. A peptide having the sequence of amino acid residue numbers 1 to 19 of SEQ ID NO: 1.
3. An isolated oligonucleotide consisting of the sequence of nucleotide numbers 1 to 57 of SEQ ID NO: l, or the corresponding or complementary mRNA sequence.
4. A peptide having the sequence shown in SEQ ID NO: l .
5. An isolated oligonucleotide consisting of the sequence shown in SEQ ID NO: l, or die corresponding or complementary mRNA sequence.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16745/95A AU1674595A (en) | 1993-12-09 | 1994-12-06 | Peptide representing antigenic epitopes of feline ige present on feline b-cells but not feline basophil cell surfaces |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16491093A | 1993-12-09 | 1993-12-09 | |
US08/164,910 | 1993-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995015977A1 true WO1995015977A1 (en) | 1995-06-15 |
Family
ID=22596621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/014407 WO1995015977A1 (en) | 1993-12-09 | 1994-12-06 | Peptide representing antigenic epitopes of feline ige present on feline b-cells but not feline basophil cell surfaces |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1674595A (en) |
WO (1) | WO1995015977A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9180189B2 (en) | 1995-07-27 | 2015-11-10 | Genentech, Inc. | Treating a mammal with a formulation comprising an antibody which binds IgE |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091313A (en) * | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
-
1994
- 1994-12-06 AU AU16745/95A patent/AU1674595A/en not_active Abandoned
- 1994-12-06 WO PCT/US1994/014407 patent/WO1995015977A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091313A (en) * | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9180189B2 (en) | 1995-07-27 | 2015-11-10 | Genentech, Inc. | Treating a mammal with a formulation comprising an antibody which binds IgE |
US9283273B2 (en) | 1995-07-27 | 2016-03-15 | Genentech, Inc. | Protein formulation |
Also Published As
Publication number | Publication date |
---|---|
AU1674595A (en) | 1995-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5091313A (en) | Antigenic epitopes of IgE present on B cell but not basophil surface | |
US5231026A (en) | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE | |
US5292867A (en) | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin | |
EP0407392B1 (en) | UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES | |
US5342924A (en) | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor | |
EP0478665B1 (en) | ANTIGENIC EPITOPES PRESENT ON MEMBRANE-BOUND BUT NOT SECRETED IgA | |
AU645783B2 (en) | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor | |
US5254671A (en) | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor | |
WO1996013593A2 (en) | Soluble single chain t cell receptors | |
US5252467A (en) | Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE | |
US5690934A (en) | Peptides relating to the extracellular membrane-bound segment of human alpha chain | |
US5260416A (en) | Antigenic epitopes present on membrane-bound but not secreted IgE | |
US5079344A (en) | Antigenic epitopes present on membrane-bound but not secreted IgA | |
US5274075A (en) | Newly identified human epsilon immunoglobulin peptides and related products | |
CA2065414C (en) | Treatment of autoimmune disease | |
EP0644896B1 (en) | PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE | |
US5514776A (en) | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface | |
US5362643A (en) | Antibodies to epitopes present on membrane-bound but not secreted IGA | |
US5310875A (en) | Peptides corresponding to membrane-bound IgA | |
WO1995015977A1 (en) | Peptide representing antigenic epitopes of feline ige present on feline b-cells but not feline basophil cell surfaces | |
AU618317C (en) | Unique antigenic epitopes on IgE-bearing B lymphocytes | |
JP2788979B2 (en) | New antibodies and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA FI HU JP KP KR LK MG MN MW NO PL RO RU SD |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |